Delayed ghrelin suppression following oral glucose tolerance test in children and adolescents with hypothalamic injury secondary to craniopharyngioma compared with obese controls

Int J Pediatr Obes. 2011 Aug;6(3-4):285-8. doi: 10.3109/17477166.2010.519388. Epub 2010 Nov 4.

Abstract

Ghrelin, released from the stomach, acts at the hypothalamus and is associated with initiation of food intake. We hypothesised that patients with craniopharyngioma and hypothalamic obesity (CRHO) would have ghrelin abnormalities. Fifteen CRHO patients and 15 BMI-matched controls underwent oral glucose tolerance test with dynamic ghrelin measurement. From 0-30 minutes, ghrelin (pg/ml) decreased less (43.4 ? 38.8 vs. 70.8 ? 35.8, p < 0.05) and insulin (pmol/l) increased more (1 669.2 ? 861.7 vs. 1 049.1 ? 560.4, p = 0.04) in CRHO compared with controls, respectively. Insulin area-under-the-curve was a weak negative predictor of the 0?30 minutes ghrelin decrease (r(2) = 0.29, p = 0.02). Delayed ghrelin suppression may contribute to obesity in CRHO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Body Mass Index
  • Case-Control Studies
  • Child
  • Craniopharyngioma / blood
  • Craniopharyngioma / complications*
  • Craniopharyngioma / physiopathology
  • Female
  • Ghrelin / blood*
  • Glucose Tolerance Test*
  • Humans
  • Hypothalamus / metabolism*
  • Hypothalamus / physiopathology
  • Insulin / blood
  • Linear Models
  • Male
  • Obesity / blood
  • Obesity / etiology*
  • Obesity / physiopathology
  • Pituitary Neoplasms / blood
  • Pituitary Neoplasms / complications*
  • Pituitary Neoplasms / physiopathology
  • Risk Assessment
  • Risk Factors
  • Time Factors

Substances

  • Biomarkers
  • Blood Glucose
  • GHRL protein, human
  • Ghrelin
  • Insulin